{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:50:52Z","timestamp":1794293452267,"version":"4.9.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.neurol.2026.02.158","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:30:41Z","timestamp":1775057441000},"page":"396-403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic updates in NMOSD and MOGAD: From present practice to future promise"],"prefix":"10.1016","volume":"182","author":[{"given":"I.","family":"Elosua-Bay\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cobo-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2026.02.158_bib0315","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.02.158_bib0320","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.02.158_bib0325","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2026.02.158_bib0330","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2026.02.158_bib0335","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.02.158_bib0340","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","article-title":"Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis","volume":"80","author":"Tur","year":"2023","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2026.02.158_bib0345","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ana.26858","article-title":"Time to disability milestones and annualized relapse rates in NMOSD and MOGAD","volume":"95","author":"Duchow","year":"2024","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2026.02.158_bib0350","doi-asserted-by":"crossref","first-page":"e200533","DOI":"10.1212\/NXI.0000000000200533","article-title":"Progression independent of relapse activity in aquaporin-4-IgG-positive NMOSD: a decade-long cohort study","volume":"13","author":"Kang","year":"2026","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2026.02.158_bib0355","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2026.02.158_bib0360","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2026.02.158_bib0365","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2026.02.158_bib0370","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.02.158_bib0375","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)\u00a0\u2013\u00a0revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2026.02.158_bib0380","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.02.158_bib0385","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.neurol.2026.02.158_bib0390","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2026.02.158_bib0395","doi-asserted-by":"crossref","first-page":"1645401","DOI":"10.3389\/fimmu.2025.1645401","article-title":"Eculizumab for the acute attack of neuromyelitis optica spectrum disorder","volume":"16","author":"Zhuang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2026.02.158_bib0400","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ene.15561","article-title":"Batoclimab as an add-on therapy in neuromyelitis optica spectrum disorder patients with acute attacks","volume":"30","author":"Wang","year":"2023","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2026.02.158_bib0405","doi-asserted-by":"crossref","first-page":"e15944","DOI":"10.1097\/MD.0000000000015944","article-title":"A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder","volume":"98","author":"Mealy","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.neurol.2026.02.158_bib0410","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.neurol.2026.02.158_bib0415","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2026.02.158_bib0420","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jnnp-2022-330360","article-title":"Time to steroids impacts visual outcome of optic neuritis in MOGAD","volume":"94","author":"Rode","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.02.158_bib0425","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jamaneurol.2024.2811","article-title":"Time to treat first acute attack of myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"81","author":"Kwon","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2026.02.158_bib0430","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1177\/13524585231184738","article-title":"Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease","volume":"29","author":"Lotan","year":"2023","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurol.2026.02.158_bib0435","doi-asserted-by":"crossref","first-page":"e213903","DOI":"10.1212\/WNL.0000000000213903","article-title":"Outcomes after acute plasma exchange for myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"105","author":"Thakolwiboon","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.02.158_bib0440","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2024-334863","article-title":"Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks","volume":"96","author":"Schwake","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.02.158_bib0445","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/jnnp-2024-333463","article-title":"Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse","volume":"95","author":"Trewin","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.02.158_bib0450","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2026.02.158_bib0455","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ene.13186","article-title":"Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder","volume":"24","author":"Chen","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2026.02.158_bib0460","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2026.02.158_bib0465","doi-asserted-by":"crossref","first-page":"e200124","DOI":"10.1212\/NXI.0000000000200124","article-title":"International Delphi Consensus on the management of AQP4-IgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab","volume":"10","author":"Paul","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"9","key":"10.1016\/j.neurol.2026.02.158_bib0470","doi-asserted-by":"crossref","first-page":"e209888","DOI":"10.1212\/WNL.0000000000209888","article-title":"Eculizumab use in neuromyelitis optica spectrum disorders: routine clinical care data from a European cohort","volume":"103","author":"Ringelstein","year":"2024","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neurol.2026.02.158_bib0475","doi-asserted-by":"crossref","first-page":"e200450","DOI":"10.1212\/NXI.0000000000200450","article-title":"Long-term efficacy and safety of satralizumab in patients with neuromyelitis optica spectrum disorder from the sakuramoon open-label extension study","volume":"12","author":"Bennett","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.neurol.2026.02.158_bib0480","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/jnnp-2024-334764","article-title":"Real-world multicentre cohort study on choices and effectiveness of immunotherapies in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"96","author":"H\u00e4u\u00dfler","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.neurol.2026.02.158_bib0485","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.02.158_bib0490","doi-asserted-by":"crossref","first-page":"103693","DOI":"10.1016\/j.autrev.2024.103693","article-title":"MOGAD: a comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally","volume":"24","author":"Trewin","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.neurol.2026.02.158_bib0495","doi-asserted-by":"crossref","first-page":"e209624","DOI":"10.1212\/WNL.0000000000209624","article-title":"Early maintenance treatment initiation and relapse risk mitigation after a first event of MOGAD in adults","volume":"103","author":"Deschamps","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2026.02.158_bib0500","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","article-title":"Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease","volume":"16","author":"Cobo-Calvo","year":"2019","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.02.158_bib0505","doi-asserted-by":"crossref","first-page":"e2142780","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom","volume":"5","author":"Satukijchai","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.neurol.2026.02.158_bib0510","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.02.158_bib0515","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1212\/NXI.0000000000000705","article-title":"Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"7","author":"Li","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2026.02.158_bib0520","doi-asserted-by":"crossref","first-page":"e2504","DOI":"10.1212\/WNL.0000000000201260","article-title":"Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease","volume":"99","author":"Barreras","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.02.158_bib0525","doi-asserted-by":"crossref","first-page":"102251","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.neurol.2026.02.158_bib0530","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2026.02.158_bib0535","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/dmcn.14336","article-title":"Rituximab in children with myelin oligodendrocyte glycoprotein antibody and relapsing neuroinflammatory disease","volume":"62","author":"Albassam","year":"2020","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.neurol.2026.02.158_bib0540","doi-asserted-by":"crossref","first-page":"953993","DOI":"10.3389\/fimmu.2022.953993","article-title":"Effectiveness and tolerability of different therapies in preventive treatment of MOG-IgG-associated disorder: a network meta-analysis","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2026.02.158_bib0545","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/jnnp-2022-330086","article-title":"Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"94","author":"Spagni","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.02.158_bib0550","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamaneurol.2022.0489","article-title":"Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin: oligodendrocyte glycoprotein antibody-associated disease","volume":"79","author":"Chen","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2026.02.158_bib0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.10.002","article-title":"Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis","volume":"289","author":"Horellou","year":"2015","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1016\/j.neurol.2026.02.158_bib0560","doi-asserted-by":"crossref","first-page":"e200401","DOI":"10.1212\/NXI.0000000000200401","article-title":"Profile and usefulness of serum cytokines to predict prognosis in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"12","author":"Villacieros-\u00c1lvarez","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.neurol.2026.02.158_bib0565","doi-asserted-by":"crossref","first-page":"e1100","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 receptor blockade in treatment-refractory MOG-IgG\u2013associated disease and neuromyelitis optica spectrum disorders","volume":"9","author":"Ringelstein","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"10.1016\/j.neurol.2026.02.158_bib0570","doi-asserted-by":"crossref","first-page":"e30421","DOI":"10.1016\/j.heliyon.2024.e30421","article-title":"Efgartigimod as rescue treatment in acute phase of neuromyelitis optica spectrum disorder: a case report","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"issue":"11","key":"10.1016\/j.neurol.2026.02.158_bib0575","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1007\/s10072-024-07678-3","article-title":"Successful treatment with efgartigimod as an add-on therapy in acute attack of anti-AQP4 antibody-positive NMOSD: a case report","volume":"45","author":"Huang","year":"2024","journal-title":"Neurol Sci"},{"issue":"10","key":"10.1016\/j.neurol.2026.02.158_bib0580","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00415-025-13408-2","article-title":"Ofatumumab treatment in patients with neuromyelitis optica spectrum disorder: a retrospective multicenter cohort study","volume":"272","author":"Yang","year":"2025","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2026.02.158_bib0585","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jocn.2022.08.020","article-title":"Autologous hematopoietic stem cell transplantation in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"105","author":"Nabizadeh","year":"2022","journal-title":"J Clin Neurosci"},{"issue":"2","key":"10.1016\/j.neurol.2026.02.158_bib0590","doi-asserted-by":"crossref","first-page":"e1134","DOI":"10.1212\/NXI.0000000000001134","article-title":"Antineonatal Fc receptor antibody treatment ameliorates MOG-IgG\u2013associated experimental autoimmune encephalomyelitis","volume":"9","author":"Remlinger","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2026.02.158_bib0595","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2026.02.158_bib0600","doi-asserted-by":"crossref","first-page":"e200340","DOI":"10.1212\/NXI.0000000000200340","article-title":"Complement activation profiles predict clinical outcomes in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"12","author":"Villacieros-\u00c1lvarez","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2026.02.158_bib0605","article-title":"Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis","volume":"24","author":"Furlan","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2026.02.158_bib0610","doi-asserted-by":"crossref","first-page":"e200292","DOI":"10.1212\/NXI.0000000000200292","article-title":"CD19-directed CAR T-cells in a patient with refractory MOGAD","volume":"11","author":"Cabrera-Maqueda","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2026.02.158_bib0615","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/brain\/awae362","article-title":"Current state and perspectives of CAR T cell therapy in central nervous system diseases","volume":"148","author":"Pfeffer","year":"2025","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.neurol.2026.02.158_bib0620","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1136\/jnnp-2024-335137","article-title":"Assessment of neuronal and glial serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease: the MULTIMOGAD study","volume":"96","author":"Marignier","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726004947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726004947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:13:44Z","timestamp":1792674824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378726004947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0035378726004947"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2026.02.158","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic updates in NMOSD and MOGAD: From present practice to future promise","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2026.02.158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}